57975-93-6

Basic information

• Product Name: N-(4-TRIFLUOROMETHYLPHENYL)ANTHRANILIC ACID
• Synonyms: N-(4-TRIFLUOROMETHYLPHENYL)ANTHRANILIC ACID;Benzoic acid, 2-[[4-(trifluoroMethyl)phenyl]aMino]-;2-((4-(trifluoromethyl)phenyl)amino)benzoic acid
• CAS NO: 57975-93-6
• Molecular Formula: C₁₄H₁₀F₃NO₂
• Molecular Weight: 281.2299096
• Product Categories: pharmacetical
• Mol File: 57975-93-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 380.46 °C at 760 mmHg
• Flash Point: 183.896 °C
• Appearance: /
• Density: 1.396 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.585
• CAS DataBase Reference: N-(4-TRIFLUOROMETHYLPHENYL)ANTHRANILIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-TRIFLUOROMETHYLPHENYL)ANTHRANILIC ACID(57975-93-6)
• EPA Substance Registry System: N-(4-TRIFLUOROMETHYLPHENYL)ANTHRANILIC ACID(57975-93-6)

Safety Data

• Hazardous Substances Data: 57975-93-6(Hazardous Substances Data)

Usage

General Description

N-(4-Trifluoromethylphenyl)anthranilic acid is a chemical compound with the molecular formula C15H10F3NO2. It is a white to off-white powder that is soluble in organic solvents. This chemical is used in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. It is also used as an intermediate in the production of dyes and pigments. Additionally, N-(4-Trifluoromethylphenyl)anthranilic acid has potential biological activity and has been studied for its anti-inflammatory and analgesic properties. It is important to handle this chemical with care and follow proper safety protocols due to its potential hazards.

InChI:InChI=1/C14H10F3NO2/c15-14(16,17)9-5-7-10(8-6-9)18-12-4-2-1-3-11(12)13(19)20/h1-8,18H,(H,19,20)

Upstream product

• 455-14-1 4-trifluoromethylphenylamine 
• 88-67-5 2-Iodobenzoic acid 
• 134-20-3 2-carbomethoxyaniline 
• 455-13-0 4-Iodobenzotrifluoride 

Downstream Products

• 13481-63-5 SKF-32802 

Relevant articles and documents

Design, synthesis and biological evaluation of N-anthraniloyl tryptamine derivatives as pleiotropic molecules for the therapy of malignant glioma

COX-2 and STAT3 are two key culprits in the glioma microenvironment. Herein, to inhibit COX-2 and block STAT3 signaling, we disclosed 27 N-anthraniloyl tryptamine compounds based on the combination of melatonin derivatives and N-substituted anthranilic acid derivatives. Among them, NP16 showed the best antiproliferative activity and moderate COX-2 inhibition. Of note, NP16 decreased the level of p-JAK2 and p-STAT3, and blocked the nuclear translocation of STAT3 in GBM cell lines. Moreover, NP16 downregulated the MMP-9 expression of BV2 cells in a co-culture system of BV2 and C6 glioma cells, abrogated the proliferative/invasive/migratory abilities of GBM cells, induced apoptosis by ROS and the Bcl-2-regulated apoptotic pathway, and induced obvious G2/M arrest in glioma cells in vitro. Furthermore, NP16 displayed favorable pharmacokinetic profiles covering long half-life (11.43 ± 0.43 h) and high blood-brain barrier permeability. Finally, NP16 effectively inhibited tumor growth, promoted the survival rate, increased the expression of E-cadherin and reduced overproduction of PGE2, MMP-9, VEGF-A and the level of p-STAT3 in tumor tissue, and improved the anxiety-like behavior in C6 glioma model. All these evidences demonstrated N-anthraniloyl tryptamine derivatives as multifunctional anti-glioma agents with high potency could drain the swamp to beat glioma.

NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME

The present invention relates to novel anthranilic acid derivatives represented by Chemical Formula I, and a chloride channel blocking agent containing the anthranilic acid derivative or its pharmacologically acceptable salts as an active ingredient. In another aspect, the present invention relates to a method of accurately and efficiently detecting the intracellular chloride channel inhibition and method of screening a chloride channel blocking agent.